<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741701</url>
  </required_header>
  <id_info>
    <org_study_id>13397</org_study_id>
    <nct_id>NCT01741701</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Oxaloacetate in Subjects With Treated PD</brief_title>
  <official_title>A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terra Biological LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective
      treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and
      complete two safety follow-up phone calls over a 4 month period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) Total Score</measure>
    <time_frame>4 months</time_frame>
    <description>The UPDRS has 3 subscales including Mentation (4 questions based on patient report with answers on a scale of 0-4, with a total of 16 points), Activities of Daily Living (13 questions based on patient report with answers on a scale of 0-4, with a total of 52 points) and Motor (27 questions based on clinician assessment on a scale of 0-4, with a total of 108 points). The total scores represents the sum of each of these sections for a total of 176 points with a higher score representing greater dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) ADL + Motor Score</measure>
    <time_frame>4 months</time_frame>
    <description>The UPDRS has 3 subscales including Mentation (4 questions based on patient report with answers on a scale of 0-4, with a total of 16 points), Activities of Daily Living (13 questions based on patient report with answers on a scale of 0-4, with a total of 52 points) and Motor (27 questions based on clinician assessment on a scale of 0-4, with a total of 108 points). This measure examined the ADL + Motor subscales which have a total of 160 points with a higher score representing greater dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionnaire - 39 (PDQ-39)</measure>
    <time_frame>4 months</time_frame>
    <description>The PDQ-39 is a measure of quality of life in Parkinson's disease patients. It has 39 questions each with a response from 0-4 for a total of 156 points. The total score is calculated as a percentage so the scores of the 39 items are added and divided by 156 and multiplied by 100. The higher the score the worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>4 months</time_frame>
    <description>The MoCA is an assessment of cognitive function. The total possible score ranges from 0 to 30 points with a lower score representing greater cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale (GDS)</measure>
    <time_frame>4 months</time_frame>
    <description>The GDS is a measure of depression. The scale has 30 yes/no questions. Each question has a maximum score of 1 and a total possible score ranging from 0 to 30. The higher the score the greater the depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NonMotor Symptom Questionnaire (NMSQuest)</measure>
    <time_frame>4 months</time_frame>
    <description>The NMSQuest is a 30 item questionnaire with 30 yes/no questions. There is a total of 30 points with each &quot;yes&quot; score representing 1 point and therefore the higher the score the greater number of nonmotor symptoms present. The score can range from 0 to 30.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Oxaloacetate (OAA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules that contain only 100 mg ascorbate, taken daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaloacetate (OAA)</intervention_name>
    <arm_group_label>Oxaloacetate (OAA)</arm_group_label>
    <other_name>benaGeneâ„¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to give informed consent and follow instructions per the protocol

          -  Diagnosis of idiopathic PD within 7 years of diagnosis

          -  Taking stable doses of levodopa and would not predictably need adjustment in PD
             medications for 4 months

          -  Unified Parkinson's Disease Rating Scale (UPDRS) II + III at least 30 points at
             baseline

        Exclusion Criteria:

          -  Previously taken Oxaloacetate

          -  Participation in other drug studies or use of other investigational products within 30
             days prior to baseline

          -  In the Investigator's opinion, any unstable or clinically significant condition that
             would impair the subjects' ability to comply with study follow-up

          -  Other known or suspected cause of parkinsonism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Pahwa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <results_first_submitted>January 18, 2016</results_first_submitted>
  <results_first_submitted_qc>February 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2016</results_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Rajesh Pahwa, MD</investigator_full_name>
    <investigator_title>Professor, Director PD and Movement Disorder Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxaloacetate (OAA)</title>
          <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxaloacetate (OAA)</title>
          <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="11.4"/>
                    <measurement group_id="B2" value="64.6" spread="9.4"/>
                    <measurement group_id="B3" value="63.4" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PD Duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="1.5"/>
                    <measurement group_id="B2" value="3.1" spread="1.7"/>
                    <measurement group_id="B3" value="3.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Unified Parkinson's Disease Rating Scale (UPDRS) Total Score</title>
        <description>The UPDRS has 3 subscales including Mentation (4 questions based on patient report with answers on a scale of 0-4, with a total of 16 points), Activities of Daily Living (13 questions based on patient report with answers on a scale of 0-4, with a total of 52 points) and Motor (27 questions based on clinician assessment on a scale of 0-4, with a total of 108 points). The total scores represents the sum of each of these sections for a total of 176 points with a higher score representing greater dysfunction.</description>
        <time_frame>4 months</time_frame>
        <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaloacetate (OAA)</title>
            <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Total Score</title>
          <description>The UPDRS has 3 subscales including Mentation (4 questions based on patient report with answers on a scale of 0-4, with a total of 16 points), Activities of Daily Living (13 questions based on patient report with answers on a scale of 0-4, with a total of 52 points) and Motor (27 questions based on clinician assessment on a scale of 0-4, with a total of 108 points). The total scores represents the sum of each of these sections for a total of 176 points with a higher score representing greater dysfunction.</description>
          <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UPDRS Total Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" spread="6.7"/>
                    <measurement group_id="O2" value="42.9" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPDRS Total Score at 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="10.4"/>
                    <measurement group_id="O2" value="34.4" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unified Parkinson's Disease Rating Scale (UPDRS) ADL + Motor Score</title>
        <description>The UPDRS has 3 subscales including Mentation (4 questions based on patient report with answers on a scale of 0-4, with a total of 16 points), Activities of Daily Living (13 questions based on patient report with answers on a scale of 0-4, with a total of 52 points) and Motor (27 questions based on clinician assessment on a scale of 0-4, with a total of 108 points). This measure examined the ADL + Motor subscales which have a total of 160 points with a higher score representing greater dysfunction.</description>
        <time_frame>4 months</time_frame>
        <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaloacetate (OAA)</title>
            <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) ADL + Motor Score</title>
          <description>The UPDRS has 3 subscales including Mentation (4 questions based on patient report with answers on a scale of 0-4, with a total of 16 points), Activities of Daily Living (13 questions based on patient report with answers on a scale of 0-4, with a total of 52 points) and Motor (27 questions based on clinician assessment on a scale of 0-4, with a total of 108 points). This measure examined the ADL + Motor subscales which have a total of 160 points with a higher score representing greater dysfunction.</description>
          <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UPDRS ADL + Motor at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="6.9"/>
                    <measurement group_id="O2" value="42.2" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPDRS ADL + Motor at 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" spread="10.2"/>
                    <measurement group_id="O2" value="33.9" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of change between groups from baseline to 4 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson's Disease Questionnaire - 39 (PDQ-39)</title>
        <description>The PDQ-39 is a measure of quality of life in Parkinson's disease patients. It has 39 questions each with a response from 0-4 for a total of 156 points. The total score is calculated as a percentage so the scores of the 39 items are added and divided by 156 and multiplied by 100. The higher the score the worse quality of life.</description>
        <time_frame>4 months</time_frame>
        <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaloacetate (OAA)</title>
            <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinson's Disease Questionnaire - 39 (PDQ-39)</title>
          <description>The PDQ-39 is a measure of quality of life in Parkinson's disease patients. It has 39 questions each with a response from 0-4 for a total of 156 points. The total score is calculated as a percentage so the scores of the 39 items are added and divided by 156 and multiplied by 100. The higher the score the worse quality of life.</description>
          <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
          <units>percentage of total possible score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PDQ-39 Total Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="8.9"/>
                    <measurement group_id="O2" value="10.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDQ-39 total score at 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="11.2"/>
                    <measurement group_id="O2" value="11.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups in the change from baseline to 4 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montreal Cognitive Assessment (MoCA)</title>
        <description>The MoCA is an assessment of cognitive function. The total possible score ranges from 0 to 30 points with a lower score representing greater cognitive impairment.</description>
        <time_frame>4 months</time_frame>
        <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaloacetate (OAA)</title>
            <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Montreal Cognitive Assessment (MoCA)</title>
          <description>The MoCA is an assessment of cognitive function. The total possible score ranges from 0 to 30 points with a lower score representing greater cognitive impairment.</description>
          <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MoCA at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="2.0"/>
                    <measurement group_id="O2" value="27.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MoCA at 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="1.6"/>
                    <measurement group_id="O2" value="27.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups in the change from baseline to 4 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.77</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geriatric Depression Scale (GDS)</title>
        <description>The GDS is a measure of depression. The scale has 30 yes/no questions. Each question has a maximum score of 1 and a total possible score ranging from 0 to 30. The higher the score the greater the depression.</description>
        <time_frame>4 months</time_frame>
        <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaloacetate (OAA)</title>
            <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Geriatric Depression Scale (GDS)</title>
          <description>The GDS is a measure of depression. The scale has 30 yes/no questions. Each question has a maximum score of 1 and a total possible score ranging from 0 to 30. The higher the score the greater the depression.</description>
          <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GDS at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="4.4"/>
                    <measurement group_id="O2" value="3.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GDS at 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="5.4"/>
                    <measurement group_id="O2" value="3.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups in change from baseline to 4 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.90</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NonMotor Symptom Questionnaire (NMSQuest)</title>
        <description>The NMSQuest is a 30 item questionnaire with 30 yes/no questions. There is a total of 30 points with each &quot;yes&quot; score representing 1 point and therefore the higher the score the greater number of nonmotor symptoms present. The score can range from 0 to 30.</description>
        <time_frame>4 months</time_frame>
        <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaloacetate (OAA)</title>
            <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>NonMotor Symptom Questionnaire (NMSQuest)</title>
          <description>The NMSQuest is a 30 item questionnaire with 30 yes/no questions. There is a total of 30 points with each &quot;yes&quot; score representing 1 point and therefore the higher the score the greater number of nonmotor symptoms present. The score can range from 0 to 30.</description>
          <population>Only subjects that completed the study were included in the efficacy analyses, those that withdrew were not included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NMSQuest at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="4.4"/>
                    <measurement group_id="O2" value="6.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NMSQuest at 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="6.3"/>
                    <measurement group_id="O2" value="6.9" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between groups in change from baseline to 4 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.95</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse effects for each subject were collected throughout the 4 month study period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxaloacetate (OAA)</title>
          <description>active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
Oxaloacetate (OAA)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo capsules that contain only 100 mg ascorbate, taken daily
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Increased urination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia/stimulant</sub_title>
                <description>Subjects had difficulty sleeping and felt jittery - described as a stimulant effect by one</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of Parkinson's disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rajesh Pahwa</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-6782</phone>
      <email>rpahwa@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

